Earnings Call · Q2 FY2021·2021-08-10

Q2 21EPS -4.08%·Rev n/aQ1 21EPS +6.34%·Rev n/aQ4 20EPS -12.93%·Rev n/aQ3 20EPS -11.70%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Timothy McCarthy — Unclear, likely a conference moderator or investor relations

Sergio Traversa — Chief Executive Officer

Charles Ence — Chief Accounting and Compliance Officer

+3.4%1d on move date+3.2% vs SPY3d−0.7%5d+3.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access